Skip to main content

Genetix Pharmaceuticals, The Provex Companies, LuckyStart, Beckman Coulter

Premium
Genetix Pharmaceuticals Signs 10,500-Square-Foot Lease in Cambridge, Mass.
 
Genetix Pharmaceuticals has signed a new lease for 10,500 square feet at Riverside Technology Center (840 Memorial Drive) in Cambridge, Mass.
 
Joe Flaherty, Tucker Hansen, and Ben Coffin of the Boston commercial real estate brokerage Meredith & Grew represented Genetix and Riverside Technology Center owner the Abbey Group in the transaction. Specifics of the deal were not disclosed.
 
Riverside Technology Center is a 130,000-square-foot laboratory building located between MIT and Harvard University, near numerous biotech businesses. Amenities include an on-site garage, a full-service cafeteria, access to Storrow Drive and the Massachusetts Turnpike, and expansive views of the Charles River and nearby Riverside Press Park.
 

 
Provex Technologies Takes 9,378 Square Feet at San Diego’s Carmel Point
 
Provex Technologies, dba the Provex Companies, a biotech startup, has signed an expansion-renewal lease at Carmel Point (15050 Avenue of Science) in San Diego. Provex signed a 62-month lease for a total 9,378 square feet, at a cost of nearly $1.5 million, according to an Aug. 8 announcement of the deal by Burnham Real Estate of San Diego.
 
The deal combines the 4,425 square feet Provex has occupied over the past six months with an expansion into another 4,953 square feet in the building.
 
Burnham’s Jim Laing represented the Provex Companies, while Richard Gonor of Grubb & Ellis | BRE Commercial represented Carmel Point, a three-building, 120,703-square-foot campus that includes 15050 Avenue of Science.
 

 
Beckman Coulter Sells 53 Acres in Kendall, Fla., to Residential Builder
 
Beckman Coulter has sold 53 vacant acres representing more than half of its Kendall, Fla., campus to LuckyStart Developers, the South Florida Business Journal  reported on Aug. 10. LuckyStart, a residential developer, paid Beckman Coulter $30 million for the land, the newspaper reported, citing first vice president Michael Silver, who represented the biotech company.